In this study, we used WGCNA to identify seven genes that are potential prognostic biomarkers for PRAD based on CNV (CCNE2, RHPN1, EZH2, TONSL, and EPHX2) and DNA hypermethylation (FMOD and SLC7A4), all of which can serve as indicators of PRAD progression and potential therapeutic targets for the PRAD treatment as well. This evidence concerns the gene EZH2 and prostate adenocarcinoma.